NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Scientific Advisory Board re: Checkpoint Inhibitors/Solid Tumor/Trial Design/Europe

Smokey21 Monday, June 13, 2016 3:47:46 PM
Re: DoGood_DoWell post# 64328 Post #
64330
of 65403 Go
And this might also be a hint of his involvement:

"Dr. Quiñones is the Principal Investigator (PI) or Co-PI on multiple clinical trials, including novel combination therapies for brain tumors (with checkpoint inhibitors and/or various other technologies)

and other technologies such as:
hub.jhu.edu/2016/06/09/predicting-speed-of-brain-cancer-spread

From the 6/13/16 Press Release:

Dr. Alfredo Quiñones-Hinojosa

Dr. Alfredo Quiñones-Hinojosa is currently Director of the Brain Tumor Surgery Program at Johns Hopkins Hospital.He is also head of the Brain Tumor Stem Cell Laboratory at Johns Hopkins. In September 2016, Dr. Quiñones will become the "William J. and Charles H. Mayo Professor" and Chair of Neurologic Surgery at the Mayo Clinic in Jacksonville, Florida, in connection with $100 million in major new construction projects being undertaken there, to develop new facilities and integrated services for complex cancers and for neurologic and neurosurgical care.

Dr. Quiñones has published 295 peer-reviewed papers and over 100 book chapters(including invited reviews and letters), and has been the main editor or section editor of nine textbooks. Most notably, Dr. Quiñones is also Editor-in-Chief for one of the most well-respected and widely-read neurosurgical textbooks in the world. Dr. Quiñones is one of the few brain surgeons with multiple research grants from the National Institutes of Health, as well as the Robert Wood Johnson Foundation and the Maryland Stem Cell Foundation. Some of his major accomplishments to date include: 1) elucidating mechanisms by which brain tumors migrate andmetastasize, 2) integrating the use of stem cells into local treatment of solid tumors, 3) the concomitant use of nanotechnology and focal beam radiotherapy in the systemic treatment of solid tumors, 4) the development of new imaging software to help identify areas within solid tumors with the greatest malignant potential, and 5) the development of innovative, minimally invasive approaches to brain tumor resection.Dr. Quiñones is the Principal Investigator (PI) or Co-PI on multiple clinical trials,including novel combination therapies for brain tumors (with checkpoint inhibitorsand/or various other technologies), and the first trials in the U.S. of certain technologies for more complete surgical removal of brain tumors.

Dr. Quiñones has been recognized with the Association of American Medical Colleges Herbert W. Nickens Award, the Johns Hopkins Hospital Department of Neurosurgery, Richard J. Otenasek, Jr, Faculty Teaching Award, the "Neurosurgeon of the Year" award from Voices Against Brain Cancer, a "Health Care Heroes Award," a Howard Hughes Medical Institute Physician-Scientist Early Career Award and various other recognitions

HERE'S DR. Q's TEAM@John Hopkins:
http://doctorqmd.com/the-team/
http://doctorqmd.com/what-we-do/

OF SPECIAL NOTE re EUROPE:

Dr. John Smyth

Dr. Smyth was appointed the first Chair of Medical Oncology in Edinburgh and, over the course of 30 years, has developed multidisciplinary oncology to create the Edinburgh Cancer Research Centre, combining laboratory and clinical research with teaching and training, and serving a population of 2 million. Dr. Smyth's research expertise is in experimental therapeutics, from drug design through all phases of pre-clinical evaluation and clinical trials, with his major research focus on the development and evaluation of new anti-cancer drugs. He Chaired the Expert Advisory Group for Oncology & Haematology for the Commission on Human Medicines, and served for several years on the UK Committee on Safety of Medicines, as well as on the Scientific Advisory Group for Oncology for the European Medicines Agency (the Europe-wide regulatory body). [color=red]Dr. Smyth also has extensive experience participating in the independent monitoring of clinical trials of checkpoint inhibitor drugs. His work has also focused on the affordability of cancer related healthcare.

Dr. Smyth has published over 300 papers and been involved in 47 books and chapters. He served as Editor-in-Chief of the European Journal of Cancer for a decade, from 2001 to 2010. He is a fellow of the Royal College of Physicians of Edinburgh and London, and fellow of the Royal Society of Edinburgh, and is a past president of the European Society of Medical Oncology and the Federation of European Cancer Societies

http://www.ecrc.ed.ac.uk/
The Edinburgh Cancer Research Centre is part of a network of Cancer Research UK Centres in the UK. It is a biomedical and clinical cancer research centre, with scientists and physicians working side by side to ultimately improve the management of cancer patients. Researchers in the Cancer Centre take a comprehensive approach to cancer research, transcending laboratory-based, computational, physical sciences and clinical disciplines. We study the genetic and biological basis of cancer, disease pathology, and work to devise and test new forms of therapy arising from our basic, translational and clinical research programmes – often in collaboration with colleagues from other disciplines or other areas of disease biology

OF SPECIAL NOTE re DCVAX DIRECT & Cancer Vaccine Trial Design & Execution:

Dr. Mac Cheever

Dr. Martin ("Mac") Cheever is the Director and Principal Investigator of the Cancer Immunotherapy Trials Network (CITN) funded by the National Cancer Institute (NCI). The CITN is a network of immunotherapy investigators who are well established and recognized academic leaders in the field of immunology at 32 leading research institutions across the U.S. Dr. Cheever also spearheaded the multi-year project to evaluate and prioritize the 20 most important investigational agents for immunotherapy and the 75 most promising cancer vaccine targets. Dr. Cheever previously served as the Director of Solid Tumor Research at the Fred Hutchinson Cancer Research Center, and continues to be a Full Member (Professor) there.

Dr. Cheever's research is focused on cancer immunotherapy, including T cell therapy and the development of cancer vaccines, especially for breast cancer. He co-founded an early biotech company developing cancer vaccines, and served as Vice President of Clinical Research and Medical Affairs for 8 years. In that capacity, he gained extensive experience with design and execution of cancer vaccine clinical trials, FDA related product approval issues and collaboration with major pharmaceutical companies.